| http://purl.uniprot.org/citations/36849939 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/36849939 | http://www.w3.org/2000/01/rdf-schema#comment | "The acute myeloid leukemia (AML) patients obtain limited benefits from current immune checkpoint blockades (ICBs), although immunotherapy have achieved encouraging success in numerous cancers. Here, we found that V-domain Ig suppressor of T cell activation (VISTA), a novel immune checkpoint, is highly expressed in primary AML cells and associated with poor prognosis of AML patients. Targeting VISTA by anti-VISTA mAb boosts T cell-mediated cytotoxicity to AML cells. Interestingly, high expression of VISTA is positively associated with hyperactive STAT3 in AML. Further evidence showed that STAT3 functions as a transcriptional regulator to modulate VISTA expression by directly binding to DNA response element of VISTA gene. We further develop a potent and selective STAT3 inhibitor W1046, which significantly suppresses AML proliferation and survival. W1046 remarkably enhances the efficacy of VISTA mAb by activating T cells via inhibition of STAT3 signaling and down-regulation of VISTA. Moreover, combination of W1046 and VISTA mAb achieves a significant anti-AML effect in vitro and in vivo. Overall, our findings confirm that VISTA is a potential target for AML therapy which transcriptionally regulated by STAT3 and provide a promising therapeutic strategy for immunotherapy of AML."xsd:string |
| http://purl.uniprot.org/citations/36849939 | http://purl.org/dc/terms/identifier | "doi:10.1186/s13045-023-01410-y"xsd:string |
| http://purl.uniprot.org/citations/36849939 | http://purl.uniprot.org/core/author | "Chen X."xsd:string |
| http://purl.uniprot.org/citations/36849939 | http://purl.uniprot.org/core/author | "Li J."xsd:string |
| http://purl.uniprot.org/citations/36849939 | http://purl.uniprot.org/core/author | "Mo J."xsd:string |
| http://purl.uniprot.org/citations/36849939 | http://purl.uniprot.org/core/author | "Lin Z."xsd:string |
| http://purl.uniprot.org/citations/36849939 | http://purl.uniprot.org/core/author | "Lou L."xsd:string |
| http://purl.uniprot.org/citations/36849939 | http://purl.uniprot.org/core/author | "Ouyang S."xsd:string |
| http://purl.uniprot.org/citations/36849939 | http://purl.uniprot.org/core/author | "Wang Y."xsd:string |
| http://purl.uniprot.org/citations/36849939 | http://purl.uniprot.org/core/author | "Zhang Q."xsd:string |
| http://purl.uniprot.org/citations/36849939 | http://purl.uniprot.org/core/author | "Zhang X."xsd:string |
| http://purl.uniprot.org/citations/36849939 | http://purl.uniprot.org/core/author | "Wen Y."xsd:string |
| http://purl.uniprot.org/citations/36849939 | http://purl.uniprot.org/core/author | "Zheng Y."xsd:string |
| http://purl.uniprot.org/citations/36849939 | http://purl.uniprot.org/core/author | "Wang P."xsd:string |
| http://purl.uniprot.org/citations/36849939 | http://purl.uniprot.org/core/author | "Zhu J."xsd:string |
| http://purl.uniprot.org/citations/36849939 | http://purl.uniprot.org/core/author | "Zhu K."xsd:string |
| http://purl.uniprot.org/citations/36849939 | http://purl.uniprot.org/core/author | "Ding W."xsd:string |
| http://purl.uniprot.org/citations/36849939 | http://purl.uniprot.org/core/author | "Deng L."xsd:string |
| http://purl.uniprot.org/citations/36849939 | http://purl.uniprot.org/core/author | "Peng K."xsd:string |
| http://purl.uniprot.org/citations/36849939 | http://purl.uniprot.org/core/author | "Yue P."xsd:string |
| http://purl.uniprot.org/citations/36849939 | http://purl.uniprot.org/core/author | "Lu J.J."xsd:string |
| http://purl.uniprot.org/citations/36849939 | http://purl.uniprot.org/core/date | "2023"xsd:gYear |
| http://purl.uniprot.org/citations/36849939 | http://purl.uniprot.org/core/name | "J Hematol Oncol"xsd:string |
| http://purl.uniprot.org/citations/36849939 | http://purl.uniprot.org/core/pages | "15"xsd:string |